Citadel Advisors
PRME icon

Citadel Advisors’s Prime Medicine PRME Stock Holding History

Citadel Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$591K Sell
160,200
-1,100
-0.7% -$3.65K ﹤0.01% 9459
2026
Q1 		$561K Sell
161,300
-27,800
-15% -$106K ﹤0.01% 9027
2025
Q4 		$656K Buy
189,100
+58,300
+45% +$259K ﹤0.01% 8357
2025
Q3 		$725K Buy
130,800
+55,200
+73% +$224K ﹤0.01% 8258
2025
Q2 		$187K Buy
75,600
+73,200
+3,050% +$113K ﹤0.01% 10736
2025
Q1 		$4.78K Sell
2,400
-40,200
-94% -$103K ﹤0.01% 13865
2024
Q4 		$124K Sell
42,600
-7,500
-15% -$26.3K ﹤0.01% 11136
2024
Q3 		$194K Sell
50,100
-23,900
-32% -$111K ﹤0.01% 10197
2024
Q2 		$380K Buy
74,000
+16,300
+28% +$98.8K ﹤0.01% 8624
2024
Q1 		$404K Buy
57,700
+15,700
+37% +$119K ﹤0.01% 8845
2023
Q4 		$372K Buy
42,000
+31,800
+312% +$245K ﹤0.01% 8711
2023
Q3 		$97.3K Buy
+10,200
New +$132K ﹤0.01% 10938

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Citadel Advisors's PRME Position: Q2 2026 in Review

Citadel Advisors increased its Prime Medicine (PRME) stake by 511% in Q2 2026, buying an estimated $5.71M and bringing the position to 2,054,543 shares worth $7.58M. The position accounts for ﹤0.01% of the portfolio, ranked #4018.

Citadel Advisors first reported a position in PRME in Q3 2023 and has held it in 9 quarters since. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Citadel Advisors held 2,054,543 shares of Prime Medicine worth $7.58M as of Q2 2026.
  • Citadel Advisors bought 1,718,185 Prime Medicine shares in Q2 2026, an estimated $5.71M.
  • Prime Medicine made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4018 holding.
  • Citadel Advisors first reported a position in Prime Medicine in Q3 2023 and has held it in 9 quarters since.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.